Randomized, Open-label and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' With Nexavar in Advanced Hepatocellular Carcinoma Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2016
At a glance
- Drugs T-lymphocyte cell therapy (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Green Cross Cell
- 07 Jun 2017 Biomarkers information updated
- 17 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 04 Mar 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018, as reported by ClinicalTrials.gov.